Wall Street analysts expect Concert Pharmaceuticals Inc (NASDAQ:CNCE) to announce earnings per share (EPS) of ($0.18) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Concert Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.53) and the highest estimate coming in at $0.17. Concert Pharmaceuticals reported earnings per share of ($0.54) during the same quarter last year, which suggests a positive year-over-year growth rate of 66.7%. The business is expected to issue its next quarterly earnings results on Monday, March 5th.
According to Zacks, analysts expect that Concert Pharmaceuticals will report full-year earnings of $4.10 per share for the current fiscal year, with EPS estimates ranging from $3.64 to $4.55. For the next fiscal year, analysts forecast that the firm will report earnings of ($2.35) per share, with EPS estimates ranging from ($2.39) to ($2.31). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Concert Pharmaceuticals.
Concert Pharmaceuticals (NASDAQ:CNCE) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.54) by ($0.16). Concert Pharmaceuticals had a negative return on equity of 51.48% and a net margin of 62.31%.
Shares of Concert Pharmaceuticals (CNCE) opened at $20.29 on Wednesday. Concert Pharmaceuticals has a 1-year low of $8.75 and a 1-year high of $30.71.
In other Concert Pharmaceuticals news, Director Ronald W. Barrett sold 14,156 shares of the company’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $24.70, for a total value of $349,653.20. Following the completion of the transaction, the director now directly owns 3,539 shares in the company, valued at approximately $87,413.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard Aldrich sold 31,236 shares of the company’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $19.14, for a total transaction of $597,857.04. Following the completion of the transaction, the director now owns 286,975 shares of the company’s stock, valued at $5,492,701.50. The disclosure for this sale can be found here. Insiders sold a total of 1,433,248 shares of company stock valued at $37,226,329 over the last 90 days. Company insiders own 10.10% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of CNCE. Acadian Asset Management LLC purchased a new stake in shares of Concert Pharmaceuticals in the 4th quarter worth about $7,713,000. Senvest Management LLC grew its position in shares of Concert Pharmaceuticals by 458.8% in the 3rd quarter. Senvest Management LLC now owns 314,629 shares of the biotechnology company’s stock worth $4,641,000 after buying an additional 258,329 shares during the period. Ingalls & Snyder LLC grew its position in shares of Concert Pharmaceuticals by 14.5% in the 3rd quarter. Ingalls & Snyder LLC now owns 1,209,062 shares of the biotechnology company’s stock worth $17,834,000 after buying an additional 153,062 shares during the period. QS Investors LLC purchased a new stake in shares of Concert Pharmaceuticals in the 2nd quarter worth about $1,294,000. Finally, Vanguard Group Inc. grew its position in shares of Concert Pharmaceuticals by 11.0% in the 2nd quarter. Vanguard Group Inc. now owns 756,513 shares of the biotechnology company’s stock worth $10,553,000 after buying an additional 74,801 shares during the period. Institutional investors and hedge funds own 67.20% of the company’s stock.
About Concert Pharmaceuticals
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.